Mike Hess

2 months ago | healio.com | Isabella Hornick |Kristen Dowd |Mike Hess

Mike Hess, MPH, RRT, RPFT This latest report from the National Vital Statistics System looks very much like many that have come before it. Heart disease remains in its traditional position atop the “leaderboard,” with longtime companions such as cancer, diabetes and various chronic diseases still filling out the top 10. On its face, the report contains few surprises for anyone in health care.

Jan 9, 2025 | healio.com | Isabella Hornick |Kristen Dowd |Mike Hess |Kevin Duan

Perspective Back to Top Mike Hess, MPH, RRT, RPFT This study by Duan and associates is statistically sound. Unfortunately, that faint praise is really all that can be offered. The authors make a variety of inexplicable assumptions and irrelevant analyses on their way to an inaccurate conclusion that jeopardizes efforts to actually improve the sorry state of oxygen therapy in America.

Oct 1, 2024 | healio.com | Isabella Hornick |Mike Hess |Kristen Dowd

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: October 2 (“O-2”) marks World Oxygen Day. Patients who use oxygen therapy currently struggle with accessing proper equipment. Clinicians can practice advocacy and share several resources to support the cause.

Apr 26, 2024 | healio.com | Isabella Hornick |Kristen Dowd |Mike Hess |David Rind

Mike Hess, MPH, RRT, RPFT The ICER report on ensifentrine provides some much-needed excitement in the world of COPD management. Ensifentrine’s novel mechanism of action (dual PDE3 and PDE4 inhibition) represents a new strategy to manage bronchospasm and inflammation, two primary drivers of COPD symptoms, simultaneously. Administration via the inhalation route will likely reduce the frequency of adverse effects reported by people with COPD using the previously approved PDE4 inhibitor, roflumilast.

Apr 5, 2024 | healio.com | Isabella Hornick |Mike Hess |Kristen Dowd

You've successfully added Practice Management in Pulmonology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:More respiratory therapists are needed following the COVID-19 pandemic. Respiratory therapists work in a variety of places.